Pharma: A second wave of generics opportunity - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: A second wave of generics opportunity

Jul 2, 2010

Generic companies thrive when a large number of drugs lose patents. This largely holds true in the US generics market. After all, it is the biggest pharma market in the world. At the same time, because of the big opportunity there, many generic companies have made a beeline for the US. And the result -competition in this space has intensified. And prices have crashed. The only way to survive in this market then is to keep up the flow of product launches. And also identify products that have limited competition. The years 2006 and 2007 were particularly good for the global generics industry. This is when a large number of blockbuster drugs went off patent. After a lull, another generics opportunity now beckons especially for Indian pharma companies.

Between the years 2011 and 2013, a large number of drugs are expected to lose patents. These drugs represent US$ 80 bn in innovator sales. Thus, even after factoring in for competition and price erosion, the opportunity available is still better than what would have been otherwise.

Making the most of it

So how are Indian pharma companies geared to capitalise on this opportunity? The crux is 'products with limited competition'.

In this regard, Dr. Reddy's, Ranbaxy, Sun Pharma, Lupin, and Glenmark have some opportunities lined up. The biggest, however, seems to lie with Dr. Reddy's and Ranbaxy.

  • Dr. Reddy's: The company has made a conscious effort of focusing on niche products so that revenue and profit potential is higher. The company has several such opportunities lined up over the next three years. These are products with exclusivity periods. Products which are difficult to manufacture. Products for which it has settled legal suits with innovator companies among others. Little wonder then that the domestic pharma major has touted the US market to be a major growth driver going forward. The company has envisaged generating sales to the tune of US$ 3 bn by 2013. And the US is expected to be a big part of it. The major challenge then to Dr. Reddy's in this market will be delay in receiving approvals for all these products.

  • Ranbaxy: The company had outlined a strategy of launching one product with the exclusivity window every year. And it was also able to strike deals in this regard. For instance, GSK Plc's 'Imitrex' was an opportunity in 2008. Then there was 'Valtrex' in 2009. 'Flomax' in 2010. And the biggest of them all 'Lipitor' in 2011. Not just that there is another opportunity in the form of 'Nexium'. The latter is the second largest drug in the world. The biggest problem for Ranbaxy is its ongoing troubles with the US FDA. And so even with an ompressive product line up, the launch of some them is uncertain. Take 'Imitrex' for example. The company lost out on the opportunity to capitalise on this drug as the approval from the US FDA got significantly delayed. The silver lining in the cloud is that it was able to launch 'Valtrex' on time. And thus amass substantial revenues from the same. Now 'Lipitor' beckons next year. Even though one can reasonably assume that Ranbaxy will do all that it can to make this launch happen, its fate will finally be decided by the US regulator.
Going forward…

It is becoming increasingly clear that Indian pharma companies will have to do something extra special. This is more so if they want to sustain their revenues and profits in the highly competitive US generics market. No longer is it a simple case of competing in the market only on the basis of price.

Equitymaster requests your view! Post a comment on "Pharma: A second wave of generics opportunity". Click here!

1 Responses to "Pharma: A second wave of generics opportunity"

K P BHAT

Jul 15, 2010

How about 1,,. PIRAMAL HEALTHCARE /2. ZYDUS WELLNESS
3.TORENT PHARM?

Like 
  
Equitymaster requests your view! Post a comment on "Pharma: A second wave of generics opportunity". Click here!

More Views on News

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Dec 1, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS